Imovax Polio (Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po)

The vaccine contains chemically inactivated whole poliovirus particles of the three serotypes. After injection, the viral antigens are processed by the immune system, prompting B‑cells to produce neutralizing antibodies and activating T‑cell responses. This immunity blocks viral replication in the gut and prevents spread to the nervous system.

The dosing schedule for Imovax Polio is determined by the prescribing healthcare professional based on age, vaccination history, and regional immunization guidelines. The prescriber will specify the number of doses, intervals, and route of administration appropriate for each patient.

Safety data for Imovax Polio in pregnancy are limited, and the product is classified as pregnancy category unknown. It should be administered only if the potential benefit justifies any potential risk to the fetus. Breastfeeding is not contraindicated, but the decision should be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the Imovax Polio product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Imovax Polio is an inactivated (killed) poliovirus vaccine, whereas oral polio vaccine (OPV) contains live attenuated virus. Inactivated vaccines cannot cause vaccine‑derived poliovirus infection and are preferred in settings where OPV‑related risks are a concern. Both provide protection against the three poliovirus serotypes, but administration routes and storage requirements differ.

Imovax Polio must be stored at 2‑8 °C in a refrigerator. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. Once reconstituted, use the vaccine promptly according to the manufacturer's instructions and discard any unused portion.

The vaccine is supplied as a lyophilized powder that is reconstituted with a sterile diluent. It is then administered by a healthcare professional via intramuscular or subcutaneous injection, typically in the deltoid or anterolateral thigh muscle, following aseptic technique.

Serious but rare risks include severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, and vaccine‑associated paralytic poliomyelitis. Immediate medical attention is required if symptoms of a severe reaction occur after vaccination.

Individuals with a known severe allergy to any component of the vaccine, or those who have experienced a previous serious reaction to an inactivated poliovirus vaccine, should not receive Imovax Polio. Additionally, severely immunocompromised patients should be evaluated carefully before vaccination.